{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T22:04:07Z","timestamp":1793829847730,"version":"4.6.1"},"reference-count":38,"publisher":"American Society of Hematology","issue":"8","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2018,2,22]]},"abstract":"<jats:title>Key Points<\/jats:title>\n               <jats:p>Selinexor is an oral XPO1 inhibitor with antimyeloma activity. The RP2D is 45 mg\/m2 (80 mg) selinexor plus 20 mg dexamethasone given twice weekly.<\/jats:p>","DOI":"10.1182\/blood-2017-08-797886","type":"journal-article","created":{"date-parts":[[2017,12,4]],"date-time":"2017-12-04T14:45:09Z","timestamp":1512398709000},"page":"855-863","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":122,"title":["Safety and efficacy of selinexor in relapsed or refractory multiple myeloma and Waldenstrom macroglobulinemia"],"prefix":"10.1182","volume":"131","author":[{"given":"Christine","family":"Chen","sequence":"first","affiliation":[{"name":"Division of Medical Oncology & Hematology, Princess Margaret Cancer Centre, Toronto, ON, Canada;"},{"name":"The University of Toronto, Toronto, ON, Canada;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Siegel","sequence":"additional","affiliation":[{"name":"Department of Hematology, John Theurer Cancer Center, Hackensack, NJ;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Gutierrez","sequence":"additional","affiliation":[{"name":"Department of Hematology, John Theurer Cancer Center, Hackensack, NJ;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meagan","family":"Jacoby","sequence":"additional","affiliation":[{"name":"Siteman Cancer Center, Washington University in Saint Louis, Saint Louis, MO;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4816-1607","authenticated-orcid":false,"given":"Craig C.","family":"Hofmeister","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Hematology, The Ohio State University, Columbus, OH;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nashat","family":"Gabrail","sequence":"additional","affiliation":[{"name":"Gabrail Cancer Institute, Canton, OH;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4538-4733","authenticated-orcid":false,"given":"Rachid","family":"Baz","sequence":"additional","affiliation":[{"name":"Department of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morten","family":"Mau-Sorensen","sequence":"additional","affiliation":[{"name":"Department of Oncology, Rigshospitalet, Copenhagen, Denmark;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jesus G.","family":"Berdeja","sequence":"additional","affiliation":[{"name":"Blood Cancer Research Program, Sarah Cannon Research Institute, Nashville, TN;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3763-5504","authenticated-orcid":false,"given":"Michael","family":"Savona","sequence":"additional","affiliation":[{"name":"Division of Hematology & Oncology, Vanderbilt-Ingram Cancer Center\/Vanderbilt University Medical Center, Nashville, TN;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lynn","family":"Savoie","sequence":"additional","affiliation":[{"name":"Tom Baker Cancer Centre Division of Hematology, University of Calgary, Calgary, AB, Canada; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzanne","family":"Trudel","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology & Hematology, Princess Margaret Cancer Centre, Toronto, ON, Canada;"},{"name":"The University of Toronto, Toronto, ON, Canada;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nuchanan","family":"Areethamsirikul","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology & Hematology, Princess Margaret Cancer Centre, Toronto, ON, Canada;"},{"name":"The University of Toronto, Toronto, ON, Canada;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T. J.","family":"Unger","sequence":"additional","affiliation":[{"name":"Karyopharm Therapeutics Inc, Newton, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tami","family":"Rashal","sequence":"additional","affiliation":[{"name":"Karyopharm Therapeutics Inc, Newton, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tim","family":"Hanke","sequence":"additional","affiliation":[{"name":"Karyopharm Therapeutics Inc, Newton, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Kauffman","sequence":"additional","affiliation":[{"name":"Karyopharm Therapeutics Inc, Newton, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharon","family":"Shacham","sequence":"additional","affiliation":[{"name":"Karyopharm Therapeutics Inc, Newton, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donna","family":"Reece","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology & Hematology, Princess Margaret Cancer Centre, Toronto, ON, Canada;"},{"name":"The University of Toronto, Toronto, ON, Canada;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"5","key":"2019111812343473800_B1","doi-asserted-by":"crossref","first-page":"E359","DOI":"10.1002\/ijc.29210","article-title":"Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012","volume":"136","author":"Ferlay","year":"2015","journal-title":"Int J Cancer"},{"issue":"1","key":"2019111812343473800_B2","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1038\/nrclinonc.2014.200","article-title":"Current treatment landscape for relapsed and\/or refractory multiple myeloma","volume":"12","author":"Dimopoulos","year":"2015","journal-title":"Nat Rev Clin Oncol"},{"issue":"10027","key":"2019111812343473800_B3","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1016\/S0140-6736(15)01120-4","article-title":"Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial","volume":"387","author":"Lonial","year":"2016","journal-title":"Lancet"},{"issue":"3","key":"2019111812343473800_B4","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1182\/blood-2014-05-573741","article-title":"Dinaciclib, a novel CDK inhibitor, demonstrates encouraging single-agent activity in patients with relapsed multiple myeloma","volume":"125","author":"Kumar","year":"2015","journal-title":"Blood"},{"issue":"9","key":"2019111812343473800_B5","doi-asserted-by":"crossref","first-page":"1820","DOI":"10.3109\/10428194.2012.661175","article-title":"Phase II trial of the pan-deacetylase inhibitor panobinostat as a single agent in advanced relapsed\/refractory multiple myeloma","volume":"53","author":"Wolf","year":"2012","journal-title":"Leuk Lymphoma"},{"issue":"8","key":"2019111812343473800_B6","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1056\/NEJMoa1606038","article-title":"Daratumumab, bortezomib, and dexamethasone for multiple myeloma","volume":"375","author":"Palumbo","year":"2016","journal-title":"N Engl J Med"},{"issue":"14","key":"2019111812343473800_B7","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1056\/NEJMoa1607751","article-title":"Daratumumab, lenalidomide, and dexamethasone for multiple myeloma","volume":"375","author":"Dimopoulos","year":"2016","journal-title":"N Engl J Med"},{"key":"2019111812343473800_B8","author":"Gravina","year":"2014"},{"issue":"12","key":"2019111812343473800_B9","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.1038\/leu.2013.172","article-title":"Genome-wide studies in multiple myeloma identify XPO1\/CRM1 as a critical target validated using the selective nuclear export inhibitor KPT-276","volume":"27","author":"Schmidt","year":"2013","journal-title":"Leukemia"},{"key":"2019111812343473800_B10","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.semcancer.2014.03.001","article-title":"Inhibition of CRM1-dependent nuclear export sensitizes malignant cells to cytotoxic and targeted agents","volume":"27","author":"Turner","year":"2014","journal-title":"Semin Cancer Biol"},{"issue":"5","key":"2019111812343473800_B11","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1158\/2159-8290.CD-13-1005","article-title":"Promising SINEs for embargoing nuclear-cytoplasmic export as an anticancer strategy","volume":"4","author":"Tan","year":"2014","journal-title":"Cancer Discov"},{"issue":"2","key":"2019111812343473800_B12","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.celrep.2012.07.007","article-title":"The oncogene eIF4E reprograms the nuclear pore complex to promote mRNA export and oncogenic transformation","volume":"2","author":"Culjkovic-Kraljacic","year":"2012","journal-title":"Cell Reports"},{"issue":"7","key":"2019111812343473800_B13","doi-asserted-by":"crossref","first-page":"960","DOI":"10.4161\/cc.8.7.8093","article-title":"The eukaryotic translation initiation factor 4E (eIF4E) and HuR RNA operons collaboratively regulate the expression of survival and proliferative genes","volume":"8","author":"Topisirovic","year":"2009","journal-title":"Cell Cycle"},{"key":"2019111812343473800_B14","author":"Osborne","year":"2015"},{"issue":"1","key":"2019111812343473800_B15","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1038\/leu.2013.115","article-title":"CRM1 inhibition induces tumor cell cytotoxicity and impairs osteoclastogenesis in multiple myeloma: molecular mechanisms and therapeutic implications","volume":"28","author":"Tai","year":"2014","journal-title":"Leukemia"},{"key":"2019111812343473800_B16","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.semcancer.2014.03.002","article-title":"Atomic basis of CRM1-cargo recognition, release and inhibition","volume":"27","author":"Fung","year":"2014","journal-title":"Semin Cancer Biol"},{"issue":"1","key":"2019111812343473800_B17","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1038\/leu.2012.219","article-title":"Antileukemic activity of nuclear export inhibitors that spare normal hematopoietic cells","volume":"27","author":"Etchin","year":"2013","journal-title":"Leukemia"},{"issue":"2","key":"2019111812343473800_B18","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1182\/blood-2012-02-412783","article-title":"Drug response in a genetically engineered mouse model of multiple myeloma is predictive of clinical efficacy","volume":"120","author":"Chesi","year":"2012","journal-title":"Blood"},{"issue":"1","key":"2019111812343473800_B19","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.rdc.2015.08.002","article-title":"Corticosteroids: mechanisms of action in health and eisease","volume":"42","author":"Ramamoorthy","year":"2016","journal-title":"Rheum Dis Clin North Am"},{"issue":"21","key":"2019111812343473800_B20","doi-asserted-by":"crossref","first-page":"Abstract 4773","DOI":"10.1182\/blood.V124.21.4773.4773","article-title":"Selinexor demonstrates marked synergy with dexamethasone (Sel-Dex) in preclinical models and in patients with heavily pretreated refractory multiple myeloma (MM) [abstract]","volume":"124","author":"Chen","year":"2014","journal-title":"Blood"},{"issue":"23","key":"2019111812343473800_B21","doi-asserted-by":"crossref","first-page":"Abstract 3683","DOI":"10.1182\/blood.V126.23.3683.3683","article-title":"Selinexor, a selective inhibitor of nuclear export (SINE) compound, shows synergistic anti-tumor activity in combination with dexamethasone characterized by specific pattern of gene expression in multiple myeloma (MM) [abstract]","volume":"126","author":"Kashyap","year":"2015","journal-title":"Blood"},{"issue":"1","key":"2019111812343473800_B22","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/leu.2008.291","article-title":"Criteria for diagnosis, staging, risk stratification and response assessment of multiple myeloma","volume":"23","author":"Kyle","year":"2009","journal-title":"Leukemia"},{"key":"2019111812343473800_B23","author":"Owen"},{"issue":"34","key":"2019111812343473800_B24","doi-asserted-by":"crossref","first-page":"4142","DOI":"10.1200\/JCO.2015.65.3949","article-title":"First-in-class, first-in-human phase I study of selinexor, a selective inhibitor of nuclear export, in patients with advanced solid tumors","volume":"34","author":"Abdul Razak","year":"2016","journal-title":"J Clin Oncol"},{"issue":"17","key":"2019111812343473800_B25","doi-asserted-by":"crossref","first-page":"3034","DOI":"10.1182\/blood-2013-04-495374","article-title":"Preclinical and clinical efficacy of XPO1\/CRM1 inhibition by the karyopherin inhibitor KPT-330 in Ph+ leukemias","volume":"122","author":"Walker","year":"2013","journal-title":"Blood"},{"issue":"12","key":"2019111812343473800_B26","doi-asserted-by":"crossref","first-page":"e113867","DOI":"10.1371\/journal.pone.0113867","article-title":"Specific inhibition of the nuclear exporter exportin-1 attenuates kidney cancer growth","volume":"9","author":"Wettersten","year":"2014","journal-title":"PLoS One"},{"issue":"26","key":"2019111812343473800_B27","doi-asserted-by":"crossref","first-page":"3166","DOI":"10.1200\/JCO.2016.67.6346","article-title":"Phase IB study of selinexor, a first-in-class inhibitor of nuclear export, in patients with advanced refractory bone or soft tissue sarcoma","volume":"34","author":"Gounder","year":"2016","journal-title":"J Clin Oncol"},{"issue":"24","key":"2019111812343473800_B28","doi-asserted-by":"crossref","first-page":"3175","DOI":"10.1182\/blood-2016-11-750174","article-title":"Selective inhibition of nuclear export with selinexor in patients with non-Hodgkin lymphoma","volume":"129","author":"Kuruvilla","year":"2017","journal-title":"Blood"},{"issue":"1","key":"2019111812343473800_B29","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1038\/leu.2011.196","article-title":"Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study [published correction appears in Leukemia. 2012;26(5):1153]","volume":"26","author":"Kumar","year":"2012","journal-title":"Leukemia"},{"issue":"11","key":"2019111812343473800_B30","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1016\/S1470-2045(13)70380-2","article-title":"Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial","volume":"14","author":"San Miguel","year":"2013","journal-title":"Lancet Oncol"},{"issue":"14","key":"2019111812343473800_B31","doi-asserted-by":"crossref","first-page":"2817","DOI":"10.1182\/blood-2012-05-425934","article-title":"A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma","volume":"120","author":"Siegel","year":"2012","journal-title":"Blood"},{"issue":"20","key":"2019111812343473800_B32","doi-asserted-by":"crossref","first-page":"2284","DOI":"10.1182\/blood-2015-05-643320","article-title":"Carfilzomib, pomalidomide, and dexamethasone for relapsed or refractory myeloma","volume":"126","author":"Shah","year":"2015","journal-title":"Blood"},{"issue":"21","key":"2019111812343473800_B33","doi-asserted-by":"crossref","first-page":"2561","DOI":"10.1182\/blood-2015-11-682518","article-title":"Randomized multicenter phase 2 study of pomalidomide, cyclophosphamide, and dexamethasone in relapsed refractory myeloma","volume":"127","author":"Baz","year":"2016","journal-title":"Blood"},{"issue":"4","key":"2019111812343473800_B34","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1182\/blood.V126.23.508.508","article-title":"Open-label, multicenter, phase 1b study of daratumumab in combination with pomalidomide and dexamethasone in patients with at least 2 lines of prior therapy and relapsed or relapsed and refractory multiple myeloma","volume":"126","author":"Chari","year":"2015","journal-title":"Blood"},{"issue":"12","key":"2019111812343473800_B35","doi-asserted-by":"crossref","first-page":"2364","DOI":"10.1038\/leu.2016.136","article-title":"Next-generation XPO1 inhibitor shows improved efficacy and in vivo tolerability in hematological malignancies","volume":"30","author":"Hing","year":"2016","journal-title":"Leukemia"},{"key":"2019111812343473800_B36","doi-asserted-by":"crossref","first-page":"4509","DOI":"10.1182\/blood.V128.22.4509.4509","article-title":"A phase 1\/2 study of the second generation selective inhibitor of nuclear export (SINE) compound, KPT-8602, in patients with relapsed refractory multiple myeloma [abstract]","volume":"128","author":"Cornell","year":"2016","journal-title":"Blood"},{"key":"2019111812343473800_B37","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1182\/blood.V128.22.491.491","article-title":"Selinexor and low dose dexamethasone (Sd) in patients with lenalidomide, pomalidomide, bortezomib, carfilzomib and anti-CD38 Ab refractory multiple myeloma (MM): STORM Study [abstract]","volume":"128","author":"Vogl","year":"2016","journal-title":"Blood"},{"key":"2019111812343473800_B38","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1182\/blood.V128.22.977.977","article-title":"Selinexor in combination with bortezomib and dexamethasone (SdB) demonstrates significant activity in patients with refractory multiple myeloma (MM) including proteasome-inhibitor refractory patients: results of the phase I STOMP Trial [abstract]","volume":"128","author":"Bahlis","year":"2016","journal-title":"Blood"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/131\/8\/855\/1466500\/blood797886.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/131\/8\/855\/1466500\/blood797886.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,18]],"date-time":"2019-11-18T12:38:40Z","timestamp":1574080720000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/131\/8\/855\/104417\/Safety-and-efficacy-of-selinexor-in-relapsed-or"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,2,22]]},"references-count":38,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2018,2,22]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2017-08-797886","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,2,22]]}}}